Leica Microsystems Inc.

Leica Microsystems Inc.'s Leica Biosystems division operates as a prime contractor to the federal government, supplying advanced microscopy equipment, laboratory instrumentation, diagnostic reagents, and associated maintenance and service agreements to civilian research and medical agencies—a for-profit subsidiary of Beckman Coulter, Inc. based in Deerfield, Illinois. The vendor competes exclusively full-and-open with no set-aside activity; all recent awards carry unrestricted, competitive designations or are sole-source awards justified on proprietary original-equipment-manufacturer grounds.

Leica Biosystems' federal footprint centers on specialized microscopy systems and histopathology instrumentation. The division delivers confocal microscopes (Stellaris, SP8, and LIAchroic series), digital slide scanners (Aperio GT450, Versa 8), automated tissue processors and stainers (BOND series, Histocore, Cerebro tracking systems), electron microscopy equipment, and consumable reagents and kits for immunohistochemistry and in-situ hybridization. Representative recent work includes a $1.47 billion service agreement with the National Institute of Allergy and Infectious Diseases covering maintenance on fourteen Leica imaging instruments across NIAID's Laboratory of Immune System Biology (base period May 2025–March 2026, four one-year option periods through March 2030); a $545.9 million maintenance and repair contract with the National Cancer Institute for three Leica systems supporting cancer research (awarded March 2025, five-year term with quarterly billing in arrears); and a $691.4 million single-award blanket purchase agreement with Veterans Integrated Service Network 15 for immunohistochemical staining instrumentation and reagents across three VA Medical Centers in the St. Louis, Kansas City, and Topeka areas (awarded June 2025, firm-fixed-price, cost-per-test model).

Customer concentration is moderate across the National Institutes of Health network and Department of Veterans Affairs. The top five funding agencies account for approximately 10% of combined potential value across the award portfolio. NIAID leads by dollars ($28.4 million across 206 awards), followed by the Veterans Integrated Service Network 12 ($25.2 million across 61 awards), FDA ($14.8 million across 153 awards), Veterans Integrated Service Network 22 ($13.1 million across 147 awards), and the National Institute on Drug Abuse ($11.9 million across 147 awards). These rankings reveal that NIAID's concentration is driven by fewer, larger contract vehicles, while VISN 12 and FDA achieve similar or greater dollars through higher award counts—a typical pattern for service-contract-intensive vendors operating across multiple regional VA networks and agency components.

Leica Biosystems holds two critical parent vehicles. The GSA Federal Supply Schedule GS24F1325C anchors the portfolio with 2,037 task orders valued at $552.7 million combined potential value—by far the largest delivery channel. A secondary GSA Multiple Award Schedule vehicle carries 586 task orders worth $41 million. Single-award blanket purchase agreements with VISN 15, VISN 19, and VISN 12 provide dedicated regional equipment and reagent procurement mechanisms. The division also holds an indefinite delivery contract with VISN 12 valued at $2.5 million for immunohistochemistry staining systems and supplies (awarded April 2026, five one-year ordering periods through March 2031).

Activity volume has decelerated. Awards per year declined from 165 in 2022 to 32 in 2026 (year-to-date through mid-August), reflecting slower procurement velocity in the recent period. Ninety-three awards are due for completion or recompete within the next twenty-four months, representing $15.4 million in combined potential value—a material recompete exposure for Leica and a competitive window for challengers in the high-volume maintenance and reagent supply market.

Service Contract Inventory coverage is limited. Across FY2022–FY2024, Leica Biosystems reported $1.7 million in SCI-captured invoiced revenue on service contracts above the $150,000 threshold, with peak activity in FY2022 ($1.6 million across 0.3 FTEs). Government-paid hourly rates on SCI-reportable contracts ranged from $1,096/hour (10th percentile) to $67,540/hour (90th percentile), with a median of $3,406/hour. SCI shows zero subcontractor hours share across prime records—the division delivers internally with no named subcontractors. This restricted SCI footprint reflects the vendor's dominant position in goods procurement (microscopes, stainers, reagents, scanners) and single-technician-per-site maintenance calls, which fall outside the $150,000-per-contract SCI reporting floor and therefore underrepresent Leica Biosystems' true federal service and revenue scale.

Leica Biosystems operates as a 100% prime contractor; four sub-awards in the source represent negligible exposure. Two are contracts (Leica Biosystems subcontracts to Roberts Oxygen Co. under an NIAID VRC operational task order for maintenance services; and a sub-role on an HHS OTA). Two are grant sub-awards (Leica as a sub-recipient on a University of Washington NIH R01 involving in vivo dual-axis confocal microscopy for low-grade glioma resection guidance, dated September 2024). The subcontract footprint does not materially characterize the vendor's posture; Leica Biosystems is a stand-alone original-equipment-manufacturer-driven prime.

Corporate structure places Leica Biosystems as a division of Beckman Coulter, Inc., a multinational life-sciences equipment and diagnostics manufacturer. The parent relationship does not alter Leica Biosystems' federal contracting identity—the division is named explicitly in all federal award documents and maintains separate SAM registration (UEI VN38G4R6FUB9) and contracting history. Beckman Coulter's broader portfolio spans clinical diagnostics, laboratory automation, and genomics instrumentation; Leica Biosystems' federal specialization in research-grade microscopy and histopathology equipment positions it as a focused, OEM-driven vendor within the larger corporate structure.